These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28915392)

  • 1. Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.
    Pereira JM; Gonçalves-Pereira J; Ribeiro O; Baptista JP; Froes F; Paiva JA
    J Crit Care; 2018 Feb; 43():183-189. PubMed ID: 28915392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
    Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
    Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
    Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
    J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
    Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
    Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic treatment strategies for community-acquired pneumonia in adults.
    Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
    N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia.
    Arnold FW; Lopardo G; Wiemken TL; Kelley R; Peyrani P; Mattingly WA; Feldman C; Gnoni M; Maurici R; Ramirez JA;
    Respir Med; 2018 Jul; 140():115-121. PubMed ID: 29957272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
    Adrie C; Schwebel C; Garrouste-Orgeas M; Vignoud L; Planquette B; Azoulay E; Kallel H; Darmon M; Souweine B; Dinh-Xuan AT; Jamali S; Zahar JR; Timsit JF;
    Crit Care; 2013 Nov; 17(6):R265. PubMed ID: 24200097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
    Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
    Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia.
    Hopkins TM; Juang P; Weaver K; Kollef MH; Betthauser KD
    Clin Ther; 2019 Dec; 41(12):2540-2548. PubMed ID: 31676040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β-lactam plus macrolide combination therapy.
    Okumura J; Shindo Y; Takahashi K; Sano M; Sugino Y; Yagi T; Taniguchi H; Saka H; Matsui S; Hasegawa Y;
    Respirology; 2018 May; 23(5):526-534. PubMed ID: 29239493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
    Paul M; Nielsen AD; Gafter-Gvili A; Tacconelli E; Andreassen S; Almanasreh N; Goldberg E; Cauda R; Frank U; Leibovici L
    Eur Respir J; 2007 Sep; 30(3):525-31. PubMed ID: 17537772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Sligl WI; Asadi L; Eurich DT; Tjosvold L; Marrie TJ; Majumdar SR
    Crit Care Med; 2014 Feb; 42(2):420-32. PubMed ID: 24158175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort.
    Ito A; Ishida T; Tokumasu H; Washio Y; Yamazaki A; Ito Y; Tachibana H
    BMC Pulm Med; 2017 May; 17(1):78. PubMed ID: 28464807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
    Williams DJ; Edwards KM; Self WH; Zhu Y; Arnold SR; McCullers JA; Ampofo K; Pavia AT; Anderson EJ; Hicks LA; Bramley AM; Jain S; Grijalva CG
    JAMA Pediatr; 2017 Dec; 171(12):1184-1191. PubMed ID: 29084336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
    Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
    Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study.
    Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
    Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.